All In Biotech

Investigational drug · Phase 2

ADG126

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced/Metastatic Solid Tumors, Solid Tumor, Advanced Liver Cancers.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

7

Any phase or sponsor naming "ADG126"

First trial start

2020

Nov 1, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ADG126", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced/Metastatic Solid Tumors
  • Solid Tumor
  • Advanced Liver Cancers

Approved drugs for the same conditions: Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "ADG126" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced/Metastatic Solid Tumors

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

  • PetosemtamabMCLA-158, GEN1158Phase 35 trials

    Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors

  • SYS6043Phase 35 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma

  • HRS-6719Phase 21 trial

    Shandong Suncadia Medicine Co., Ltd. · Advanced/Metastatic Solid Tumors

  • SYS6088Phase 21 trial

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced/Metastatic Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.